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Abstract  
Globally 1.8 million children are estimated to be living with HIV, yet only 51% of those eligible 
actually start treatment. The completion of research and development (R&D) for paediatric 
antiretrovirals (ARVs) is a lengthy process and licensing of new paediatric ARVs continues to lag 
considerably behind adults. Providing safe, effective, and well-tolerated drugs for children remains 
critical to ensuring scale-up of paediatric treatment globally. In this manuscript we review current 
approaches to R&D for paediatric ARVs and suggest innovations to enable simplified, faster, and 
more comprehensive strategies to develop optimal formulations. Several approaches could be 
adopted, including enrolment of multiple age-cohorts concurrently and the early introduction of 
dosing approaches for both single and fixed-dose combination (FDC) drug formulations (preferably 
scored and dispersible) that match WHO weight-bands. Efforts to speed up development of optimal 
drugs and formulations for children should focus on a limited number of prioritised formulations. 
This work should build upon existing partnerships and collaborations to ensure that paediatric 
investigation plans are developed early in the drug development process but can be modified in a 
streamlined manner as more information becomes available. In addition, simplified and more 
efficient mechanisms to undertake R&D need to be put in place, and financing mechanisms must be 
made more efficient and sustainable. Registration, implementation, and strategic use of drugs 
should not be seen as a sequential process, with research designed to address multiple questions 
simultaneously to respond to the needs of HIV-infected children where they live. It is imperative that 
lessons learned from HIV should be shared to support progress in developing paediatric formulations 
for other diseases with similar treatment challenges, including tuberculosis and viral hepatitis. 
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Background  
Globally, 1.8 million children are currently estimated to be living with HIV 1, 95% living in sub-
Saharan Africa2. New World Health Organization (WHO) treatment recommendations state that all 
children should start antiretroviral therapy (ART) irrespective of their clinical and immunological 
status, which is set to increase the number of children now eligible for ART3. Benefits of early 
treatment include decreased mortality and morbidity, improved survival, growth and 
neurodevelopment, and prevention of pubertal and cognitive delays4. Yet only half of children 
eligible for ART globally actually receive it2 and much more needs to be done to ensure sustainable 
supplies of effective and well-tolerated drugs for children if we are to successfully scale-up of 
paediatric treatment to achieve global targets5 and to ensure sustained virological suppression in 
HIV-positive children. 2  
 
HIV treatment research and development (R&D) has been a highly innovative and fast moving area 
of infectious disease medicine. Innovations have continually been introduced by originator and 
generic manufacturers that have marketed compounds to maximise efficacy, minimise toxicity and 
pill burden, and optimise drug sequencing. This has been coupled with important initiatives dealing 
with intellectual property (IP) that have allowed generic manufacturers to collaborate with 
originators and engage with reliable production and swift development of fixed-dose combinations 
(FDCs)6. These new formulations have shown to improve rates of adherence compared to separate-
pill regimens and have provided programmatic advantages by simplifying procurement and supply 
management as well as prescribing practices and administration7,8.  
 
Unfortunately, infants and children have benefited less than adolescents and adults from this 
progress. Around a quarter of antiretroviral (ARV) medicines and combinations approved by the US 
Food and Drug Administration (FDA) (12 of 46) or the European Medicine Agency (EMA) (8 of 30) for 
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adults are approved for use in children below 2 years9,10. The decreasing number of new paediatric 
infections – as a result of major advances in reduction of mother-to-child transmission – has further 
de-incentivised manufacturers to engage with paediatric drug development, despite ongoing 
additional need for better drugs for first- and second-line treatment with children needing life-long 
treatment. Although existing regulatory frameworks have made paediatric drug development a 
requirement for approval of adult formulations, to date the completion of paediatric R&D plans has 
been lengthy, slow, and insufficiently streamlined to focus on priority formulations.  
 
While treatment guidelines have strived to recommend the best available treatment for those in 
need, implementation of these guidelines for children has been challenging for several reasons, 
including lack of age-appropriate formulations and mis-alignment with preferred regimens for 
adolescents and adults. The global paediatric community has now established a set of priority 
formulations to maximise drug efficacy and safety and optimise drug sequencing, and has 
established platforms to support the different stages of drug development and product 
introduction.11  Increasing therapeutic options for children is critical, but it is also important that 
these efforts remain focused to avoid market fragmentation and promote programme simplification. 
The establishment of a limited set of optimal formulations is considered important to ensure 
sustainability of production and effective procurement12. The work undertaken as part of the drug 
optimisation agenda has largely clarified what the urgently needed paediatric ARV formulations are, 
yet the process from R&D to regulatory approval and availability of medicines in country needs to be 
accelerated. 
 
In this manuscript we review current approaches to R&D for paediatric ARVs and suggest 
innovations to enable simplified, faster and more comprehensive strategies to develop optimal 
formulations that will ultimately support scale-up of treatment for all infants and children living with 
HIV. 
  6 
 
The long road from drug discovery, formulation development, to patients  
 
To date, paediatric drug development has received less attention and funding than drug 
development targeting adults, resulting in fewer appropriately labelled paediatric drugs and fewer 
age-appropriate dosage forms. To try to improve the situation, the FDA and the EMA have 
developed specific regulations to incentivise paediatric drug development. Paediatric assessments 
have been required and incentivized by the FDA in initiatives beginning in 1994 and codified into law 
as the Best Pharmaceuticals for Children Act (2002) and the Pediatric Research Equity Act (2003); 
and both continue to this day1314. In Europe, the Paediatric Regulation entered into force in 2007 
requiring all companies seeking drug registration for adults to establish a paediatric drug 
development programme15. The WHO Prequalification Programme does not have specific paediatric 
regulation requirements but has nevertheless been a critical enabler to introduce paediatric FDCs in 
countries with the highest burden of disease (Table 1). 
 
Table 1. Key features of Stringent Regulatory Authority (SRAs) requirements to develop 
paediatric medicines.  
Theoretically the PIP in the EU is required to be submitted to the EMA upon availability of adult pharmacokinetic studies, 
which means at an early phase of a new drug development plan (after phase I). The PSP in the US must be submitted 
shortly after Phase 2 development when there is preliminary evidence of efficacy in adults. In both regions, at an early 
stage of the development strategy, direct support and advice from competent authorities can be obtained. In addition, 
regular monthly teleconferences are taking place between the major stringent regulatory authorities (EU, US with Japan, 
Canada, Australia) to discuss possible differences of approaches. The EMA and FDA are in fact working to develop 
‘compatible’ paediatric programmes to avoid exposing children to unnecessary trials. 
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SRAs Requirements 
European Medicines 
Agency 
 All new medicines and fixed-dose combinations (FDCs) 
developed must have a Paediatric Investigation Plan (PIP) 
agreed, before the marketing authorisation application is 
submitted (both for the adult and paediatric population). 
 A PIP should be agreed even when a marketing-authorisation 
holder wants to add a new indication, pharmaceutical form, or 
route of administration for a medicine that is already 
authorised and covered by intellectual property rights. 
 As a reward for completing the paediatric development an 
extension of the drug patent is granted at national level, thus 
incentivising research and development (R&D) companies to 
plan early the paediatric developments.  
 The PIP for a medicine can be modified at a later stage as 
knowledge increases. Modifications can also be made if the 
applicant encounters such difficulties with the implementation 
of a PIP, which render it unworkable or no longer appropriate.  
 PIP deferrals can be granted. These allow an applicant to delay 
development of the medicine in children until, for instance, 
there is enough information to demonstrate its effectiveness 
and safety in adults.  
 Waivers can be granted when development of a medicine in 
children is not needed or is not appropriate, such as for 
diseases that only affect the adult population. 
US Food and Drug 
Administration 
 All new medicines or FDCs must have a Pediatric Study Plan 
(PSP) agreed upon prior to filing the New Drug Application 
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(NDA). Except under specific circumstances, this is required at 
the end of Phase II development. The PSP outlines the 
sponsor’s paediatric development programme and their plans 
to request a deferral, waiver, or partial waiver when they file 
the NDA. 
 At the time of filing the NDA, the pharmaceutical sponsor can 
request a deferral of paediatric studies if the drug is otherwise 
ready for approval and paediatric studies have not been 
completed. A waiver of paediatric studies can be requested if: 
1) clinical trials in one or more paediatric age-groups are 
determined to be impossible or highly impractical to conduct; 
2) there is evidence the drug would be unsafe or ineffective in 
paediatric patients; 3) the product does not represent a 
meaningful therapeutic benefit over existing therapies and is 
not likely to be used in a substantial number of paediatric 
patients; or 4) the sponsor can demonstrate that reasonable 
attempts to produce a formulation necessary for that age-
group have failed. 
WHO Prequalification 
Programme 
 In close cooperation with national regulatory agencies and 
partner organisations, the WHO Prequalification Programme 
undertake evaluation and inspection activities, and build 
national capacity for sustainable manufacturing and 
monitoring of quality medicines.  
 Comprehensively evaluate the quality, safety, and efficacy of 
medicinal products, based on information submitted by the 
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manufacturers, and inspection of the corresponding 
manufacturing and clinical sites.  
 Prequalify quality control laboratories of pharmaceuticals and 
build the capacity of staff from national regulatory authorities, 
quality control laboratories, and from manufacturers or other 
private companies, to ensure medicines quality.  
 The list of prequalified medicinal products has become a vital 
tool for any agency or organisation involved in bulk purchasing 
of medicines, be this at country level, or at international level, 
as demonstrated by the Global Fund to Fight AIDS, 
Tuberculosis and Malaria. 
 
 
 
 
Drug and formulation development is a sequential process, starting with identifying therapeutic 
targets, developing screening tools, screening molecules, identifying and optimizing lead compounds 
before preclinical toxicity evaluations and absorption, distribution, metabolism, and excretion 
studies. It is only after all these studies have been completed that a drug candidate can be tested in 
human beings. Phase 1 studies in healthy volunteers examine pharmacokinetics (PK)/short-term 
safety and Phase 2 studies in HIV infected individuals and continue to evaluate dose-finding, longer 
term safety, and preliminary evidence of efficacy. It is generally only at this stage that paediatric 
drug development is envisaged, with the design of a Paediatric Investigation Plan (PIP) and/or a 
Paediatric Study Plan (PSP) and its submission to stringent regulatory authorities (SRAs), the FDA, 
and the EMA. EMA PIPs are usually submitted at the end of the Phase I study, FDA PSPs are 
submitted at the end of Phase II.  
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The way paediatric FDCs of ARVs have historically been developed – with the aim of improving 
adherence in children and simplify procurement and supply – requires multiple stages with barriers 
translating into serious delays. The process, as illustrated in Fig 1, typically included starting with 
investigating a new single-agent drug in an age-staggered (ie. testing a drug in an older age cohort, 
then sequentially moving to the next lower age cohort) dose-finding and safety study supported by 
extrapolation of efficacy from adult trial data that would allow SRA approval typically obtained in an 
age-staggered fashion. For inclusion in global treatment guidelines, the drug would ideally be used in 
studies to explore efficacy compared to a standard of care where possible, and then introduced in 
treatment guidelines using a weight-band dosing algorithm. PK and clinical data for all component 
drugs in a proposed FDC would need to be modelled and validated to identify optimal drug ratios, 
after which the FDC could then be formulated. The candidate FDC formulation would then require 
bioequivalence testing and complete stability data in order to obtain regulatory approval and in 
country registration for final market introduction. 
 
Fig 1: Development and introduction of fixed-dose combinations (FDCs) for children living 
with HIV. 
 
 
A number of issues merit consideration. While an age-staggered approach to paediatric drug 
development was intended to protect the youngest children from potential additional toxicity or lack 
of efficacy that may result from known or unknown differences in drugs absorption and metabolism, 
there is no rationale for having a fully age-staggered approach based on the existing age bands (12-
18 years, 6-12 years, 2-6 years, 4 weeks to 2 years, birth to 4 weeks). Most differences (from adults 
and older children in weight-adjusted dose or surface-area-adjusted dose) are confined to neonates 
(birth to 4 weeks) and in infants and young children (4 weeks-2 years). This is due to developmental 
differences in the physiologic processes underlying drug absorption, distribution, metabolism, and 
excretion,16 and developmental changes in diet and feeding pattern. As a result, drug dosing 
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regimens for neonates and young infants often cannot be extrapolated from those used in older 
children and adults but must be developed based on further age-specific PK data.17  When 
appropriate formulations are not developed early enough in the drug development plan, this can 
have a particular impact on the timeline for drug approval across the age spectrum, and ultimately 
affect introduction of critical therapeutic options in treatment guidelines.  
 
For simplification and ease of implementation, the WHO has established paediatric ARV doses 
expressed per weight-band rather than per kilogram or per square metre of body surface area18. The 
approval of drug dosing, which optimises drug exposure for the individual but does not consider 
weight-band dosing recommendations, can generate a critical mis-match between the SRA-approved 
drug label and the ultimate use of the drug. As a result, pragmatic recommendations based on WHO 
weight-bands require an additional step to validate those dosing recommendations. The validation 
of weight-band dosing should preferably be supported by data; however, conducting such studies in 
the population of interest can be challenging and they are often undertaken as sub-studies of larger 
treatment strategy studies that may have long timelines for completion. 
 
Another key challenge is our ability to conduct studies in the target population. As maternal ART is 
scaled up and the number of new HIV infections progressively decrease, enrolment of infants and 
children in drug trials will become more difficult, particularly when particular indications are sought 
(ie, drug naive, class-naïve, or treatment-experienced patients). In addition, studying a drug when 
there is no intention by policy-makers to prioritise it and support its market introduction may also 
present an ethical concern that ethics review boards may need to consider, further limiting the 
ability to recruit patients into studies in a timely manner. 
 
Combining multiple drugs in a single formulation can be challenging because of compound 
compatibility, solubility, stability, absorption characteristics, pharmacokinetics, or palatability. As in 
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the case of a lopinavir and ritonavir (LPV/r) paediatric solid co-formulation, additional 
biopharmaceutical development to verify the compatibility of the separate drugs, their joint stability, 
taste evaluation, dissolution, as well as phase 1 bioequivalence studies, were required. 
 
Finally, individual drug dosing recommendations may not be suitable for simple ratio and dosing 
across all weight or age-groups and merging existing datasets to undertake PK modelling may be 
required. In addition, generic manufacturers engaging with the development of formulations need 
to undertake bioequivalence studies and demonstrate that the same quantity of active ingredients 
leads to the same drug exposure as that of the originator product (or products) of reference (i.e. 
show bio-equivalence). The lack of a reference product against which to compare bioequivalence 
requires comparison with originator products such as paediatric liquid formulations, which may not 
have comparable bioequivalence to solid formulations (eg. 3TC liquid and dispersible tablets; or 
LPV/r liquid and solid formulations). This has led to additional complexity and further delays in 
gathering the data required to develop and approve a new formulation of one or multiple ARVs. 
 
Opportunities for change  
 
Certain diseases such as diabetes or asthma have specific characteristics in adults or children and 
treatment efficacy may differ in the two populations. By contrast, treatment of HIV and other 
infectious diseases is based on anti-infectives directed against the specific pathogen and often the 
same treatment outcomes are expected irrespective of the subpopulation considered, provided that 
drug exposure lies within the therapeutic range established in adults. For this reason, extrapolation 
of efficacy from adult drug trials has informed ART treatment guidelines to manage children living 
with HIV. 
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In this context, fully powered phase III efficacy trials for ARVs in children are unlikely to be needed. 
However, dosing and safety remain of paramount importance and innovative approaches can be 
adopted to speed up generation of the necessary data. For instance, phase I and II safety and dose-
finding trials included in PIPs and PSPs – that have been historically conducted in an age-staggered 
approach, as requested in the past by regulators such as EMA19 – could be expedited and happen 
simultaneously for all children older than 2 years. In addition, if there are no specific clinical 
concerns this could even occur from 4 weeks of age. Importantly, this depends upon developing age-
appropriate formulations and assessing drug exposure early in the drug development life cycle, 
rather than at a later stage in the drug development plan after the adult development is complete. 
 
As age is de-emphasised in the design of such trials, opportunities arise to directly explore dosing 
schedules based on weight bands. Enrolling subjects based on weight-band strata in initial paediatric 
PK trials, provided that adult data support this approach, would enable generation of PK data that 
directly inform the use of the drug according to WHO weight-bands and would remove the need to 
conduct PK and clinical studies to validate dosing schedules developed post-hoc.  
 
Obtaining good quality pharmacokinetic data is crucial to determining appropriate dosing and to 
inform the optimal ratio to enable development of FDCs of existing drugs20. Regulators recognise 
that PK data, which demonstrates similar drug exposure to that observed in adults, can be used to 
extrapolate clinical efficacy under certain conditions and – to a certain extent – safety in paediatric 
patients21. Differences in patient physiology can influence the concentration of drug within the 
plasma or tissue, but the most noticeable differences have been reported in neonates and children 
younger than 2 years. For these reasons, a number of innovative approaches should be encouraged 
to speed up enrolment and generation of critical information to inform drug development (Fig 2). 
These approaches could include: 
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1. PK modelling to develop FDC of approved drugs: WHO gives preference to recommending age-
appropriate FDCs for any regimen for children if such a formulation is available. To develop FDCs 
of approved drugs PK modelling should be used. The Paediatric Antiretroviral Working Group 
(PAWG) has put forward weight-band dosing of EFV/ABC/3TC FDC for children 3-10 years of age 
based on PK modelling which has received preliminary FDA support22. 
2. Investigate the washout period from maternal ARVs to inform PK studies for the first days of life: 
The neonatal period is the most challenging from the PK perspective and only five ARVs are 
currently FDA approved for use in neonates less than 14 days of age. Because very early 
diagnosis and treatment is recommended there is a need for more research on ARVs for 
neonates. Research should be done in newborns to study the washout PK and safety of ARVs 
given to the mother during pregnancy and labour. Such data would then inform dosing that 
would be studied in a formal PK study of this age-group. The International Maternal Pediatric 
Adolescent AIDS Clinical Trials (IMPAACT) P1097 was designed to describe the washout PK and 
safety of in utero/intrapartum exposure to raltegravir in full-term neonates born to HIV-infected 
pregnant women who received raltegravir-based ART during pregnancy23.  A similar study is 
planned for dolutegravir. 
 
Fig 2: Strategies to innovate research and speed up collection of critical data to develop and 
introduce paediatric drug and formulations more rapidly 
 
 
Nevertheless, there may be instances where there is a strong rationale for conducting efficacy trials, 
for example in a subset of the population with specific characteristics such as neonates and older 
infants who have typically high viral load counts, who rapidly progress to AIDS, and whose resistance 
profile may be affected by exposure to maternal ARVs. Given that recruitment of such a trial 
population would be extremely difficult, there is a need to use innovative trial designs24. Some 
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efficiency could be gained by adopting alternative study designs (Table 2). Multi-arm multi-stage 
(MAMS) designs for examples offer the opportunity to adapt trial and/or enrolment procedures 
after its initiation without undermining the validity and integrity of the trial25. Adaptations could 
include adaptive randomisation, sample size re-estimation, dose-finding design, or comparator drug 
regimen. Bayesian trials offer the opportunity to substantially decrease the number of children 
required by using existing evidence to make a priori assumptions about likely outcomes.26 Factorial 
trials allow for the investigation of a number of questions within a single trial, and could be a useful 
approach. 
 
Table 2: Innovating trial designs to increase efficiency of clinical efficacy trials for paediatric 
treatment 
Multi-arm multi-stage (MAMS) designs: these offer the opportunity to adapt to trial and/or 
enrolment procedures of the trial after its initiation without undermining the validity and integrity of 
the trial. The purpose is to shorten the development process (speed) without compromising the 
safety and efficacy of the drug product under investigation (validity) by maximising the power for 
identify best clinical benefit of the drug product under investigation with limited number of subjects 
(efficacy)5. This approach was used to develop a child-friendly fixed-dose artemisinin combination 
therapy (ACT) of pyronaridine and artesunate (Pyramax)27. 
Bayesian trials: these offer the opportunity to substantially decrease the number of children 
required by formally leveraging the evidence available. This approach is particularly efficient when 
assessing the effect of therapeutic agents on a rare event. The PHPT-528 trial investigated the 
effected of enhanced postnatal prophylaxis in children at high risk of mother-to-child transmission. A 
meta-analysis of all perinatal prevention trials done in the same populations was performed (n= 
3965) and intrapartum transmission modelled to generate initial transmission probabilities in high- 
risk children with and without an enhanced postnatal prophylaxis. During the following prospective 
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trial where children at low risk of transmission received no postnatal ARV intensification and 
children at high risk (per partum detectable via maternal viral load) received postnatal 
intensification, initial transmission were updated and the study stopped after inclusion of 88 high 
risk infants with no intrapartum transmission. The modelled posterior Bayesian transmission 
probability in high-risk infants receiving single-drug prophylaxis was 2% (95%CI: 0.3%-5.2%) whereas 
it was 0.4% (95% CI: 0.1%-1.4%) in children receiving 3-drugs prophylaxis. The probability of 
superiority of intensification over single drug prophylaxis was 94% and that of at least a 2-fold 
reduction of risk was 83%.29 30 31 
Factorial design: these trials allow investigation of a number of questions at the same time and 
maximise the amount of data collected as a result of a randomised trial. The ARROW trial was a 5-
year trial conducted in Uganda and Zimbabwe and had a number of randomisations. The key initial 
randomisations were to three different first-line regimens and, in a factorial design, to two 
monitoring strategies. An opportunity was taken in this long-term trial to add two further 
randomisations: to once versus twice daily dosing of abacavir and lamivudine and to stop or 
continue cotrimoxazole. Finally, a number of PK sub-studies were undertaken within the trial thus 
maximising efficiency. 
 
 
 
 
 
Fig 3.  Translating Novel Approaches: Potential Immediate applications to the development of 
DTG/TAF/FTC  
Experts agree that DTG/TAF/XTC represent the most promising combination for an optimised paediatric first-line regimen 
across all age-groups and weight bands. This regimen could also align with that for adults, but there are a number of steps 
and barriers before it will be available as a child-friendly fixed-dose combination (FDCs). DTG is currently under evaluation 
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in IMPAACT P1093, an ongoing phase I and II, multicentre, open-label, pharmacokinetic (PK), dose finding and safety study 
of DTG plus optimised background regimen in infants, children, and adolescents. This evaluation takes a staggered 
approach with de-escalated, age-defined cohorts. ODYSSEY (PENTA 20) is a phase II and III randomised non-inferiority trial 
that will compare once daily DTG plus two NRTIs to standard therapy. This is a multi-country study in 700 children aged 18 
years or younger either starting first-line (n=310) or switching to second line ART (n=390). The primary endpoint is time to 
virological failure (>400 copies/mL) over 96 weeks and it will include a substudy to confirm the DTG dose with concomitant 
rifampicin-containing TB treatment. These two trials should be able to capture enough PK and clinical data to inform 
weight-band dosing using the existing dosage strengths.  
Tenofovir alafenamide fumarate (TAF) is approved by FDA and the EMA as part of an FDC containing 
elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) for adolescents aged 12 years and older weighing at least 35 kg. This 
study is ongoing in treatment-naive children and adolescents aged six to18 years.[8] TAF is also being studied in paediatric 
patients as a co-formulation with FTC in a phase 2/3 switch study. Children and adolescents aged 6 to 18 years will switch 
their current NRTI-containing regimen to F/TAF (while continuing on their third antiretroviral agent) for 96 weeks. A TAF 
study in infants and children aged 4 weeks to 6 years is planned but at present there is no clear timeline. Reduced dose 
tablets and a non-solid formulation are in development.  
 
 
Furthermore, in the context of serving different populations and ensuring that the formulations are 
targeted to the population with the highest burden of the disease, acceptability and feasibility of the 
formulations are critical elements to assess from the early steps of formulations development and to 
potentially require in dose finding and safety trials. Ensuring that acceptability data are robust 
without adding another layer of complexity is an important goal that needs to be more fully 
explored.  
 
Continuing to promote innovations  
 
Long-acting formulations and alternative drug-delivery systems such as implants or pouches, should 
be considered when developing a long-term vision for treating infants, children, and adolescents 
living with HIV. In addition new treatment strategies ought to be explored with the goal of 
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optimising the drug sequencing of drugs in the context of limited options for this life-long treatment 
required by patients. 
 
Existing regulatory frameworks promote development of paediatric formulations, but 
implementation of those frameworks has resulted in delays and inefficient allocation of resources, 
with R&D investments channelled towards formulations that are not expected to meet the needs of 
the population of interest. As of November 2014, of the 22 PIPs submitted to the EMA, only five 
were considered priority formulations according the PADO priority list32. In addition, the success in 
preventing mother-to-child transmission has reduced the number of new HIV infections, making it 
increasingly challenging to conduct robust clinical studies to assess all new paediatric drugs and FDCs 
across the age spectrum, particularly in infants and young children. 
 
For these reasons, in order to ensure the sustainability of new approaches to develop new paediatric 
drugs and formulations, there is an urgent needs to develop alternative financing mechanisms that 
build upon existing regulatory processes, optimise the investment in paediatric ARVs, maximise the 
paediatric expertise available in the HIV community, and enable a more sustainable development of 
prioritised products. Approaches that focus regulatory requirements on unmet paediatric needs can 
free resources to support the development of priority formulations. This requires promoting an open 
dialogue between manufacturers, policy makers, research networks, regulatory agencies, and other 
relevant stakeholders. Assessing feasibility and developing concrete next steps to innovate financing 
of paediatric R&D must be explored, leveraging the political commitment generated by the adoption 
of a specific resolution on paediatric medicines during the most recent 69th World Health 
Assembly33. 
 
It is worth noting too that the challenges of paediatric drug development for HIV are similar 
challenges to other infectious diseases that are common in low- and middle-income countries  – 
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including, tuberculosis34 35, malaria36, and viral hepatitis37. For these other priority diseases, drug 
optimisation principles should also be used to target R&D efforts. The lessons learned from the 
rapidly evolving field of HIV treatment should be used to ensure that neonates, infants, and children 
are not left behind. 
 
Conclusions  
  
As the global community strives to reach ambitious treatment goals for HIV5, with the aim of 
ensuring 90% of all HIV positive people globally are receiving sustained ART by 2020, providing the 
right medicine to children remains a critical imperative for policy makers as well as for the research 
community. Meeting global treatment targets will require new ways to develop the most potent and 
tolerable drugs in formulations that are appropriate for infants and children living with HIV.  
 
While the knowledge and the framework to develop paediatric drugs and formulations are available, 
with important progress made over the last decade, new efforts are clearly needed to accelerate 
development of optimal drugs and formulations for children. In an era when a new drug such as 
dolutegravir is approved by SRAs in 2014, included in WHO guidelines in 2015, and is expected to 
become available for adults in low- and middle-income countries via generic production at the end 
of 2016, the substantial delays in paediatric formulations development and introduction are now 
unacceptable. Furthermore, life-long daily triple ART cannot be our goal for children living with HIV: 
innovative delivery mechanisms as well as new therapeutic strategies need to be investigated. 
 
The research community can play an essential role by driving innovations with rigorous but 
simplified approaches. The simultaneous enrolment of different age cohorts, the investigation of 
WHO-weight band dosing in any paediatric development plan, the concomitant assessment of 
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acceptability and feasibility while products are developed, and the use of PK modelling to inform 
dosing as well as a more efficient study designs, are all innovations that have the potential to speed 
up the generation of the evidence required to inform development and introduction of the most 
optimal formulations. Registration, implementation, and strategic use of drugs should not be seen as 
a sequential process, and research should be designed to address multiple questions simultaneously 
to respond to the needs of HIV-infected children where they live. This will mean anticipating the 
future challenges posed by selection of HIV drug resistance and the programmatic reality as well as 
the shifting landscape of the HIV epidemic. 
 
These innovations will have to occur as part of a strategic and pragmatic approach to product 
prioritisation that takes into account the programmatic reality. They must acknowledge the 
constraints of the exiting regulatory framework as well as the lack of incentives for manufacturers to 
develop paediatric formulations. Efforts should focus on a limited number of optimal formulations 
and build upon existing partnerships and collaborations to ensure that PIPs are developed from the 
early stage in consultation with the scientific community, that simplified and more efficient 
mechanisms to undertake R&D are put in place, and that the knowledge and the enrolment capacity 
of existing research networks is maximised. It will be vital that we ensure collaboration and 
coordination between research community, pharmaceutical companies, regulators, and policy 
makers. This will require the funding and the political will to keep paediatric development outside of 
current market dynamics and to develop innovative financing mechanisms that can be sustained 
over time. 
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•Children other than young infants (<2 years)  should be recruited without a staggered 
approach, if no specific concerns are present.
Simultaneous enrolment of different age cohorts
•All antiretrovirals trial protocols in children should be performed following the weight-
band-based approach.
Inclusion of WHO weight-band-based dosing in PIP/PSP 
•Collection and analysis of PK data should be optimised as much as possible.
•PK modelling
•Initiate a wash out period
Optimize use of PK data and PK modelling
•More innovative trials should be performed in HIV-infected children, including adaptive 
design, Bayesian approach, or opportunistic studies to shorten the development process 
of ARVs in children and have them available sooner.  
Consider alternative study designs
Assess acceptability and feasibility 
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DTG/ TAF/ FTC 
General Approaches 
 Expedite access to needed data including DTG individual drug dosing from 
IMPAACT 1093 and combined F/TAF dosing from Gilead studies 
 Engage MPP/ PHTI/ generics and other partners now to begin manufacturing 
process  
 Consider creating small batches of possible combination doses to “jump 
start” manufacturing process 
 Consider a scored dispersible adult tablet for use in older children 
 
Age and Weight Specific Approaches 
 Simultaneous enrolment into studies across weight and age and ensure 
enrolment across various weight bands  
 Ensure rapid PK results (in as real time as possible) for in-study dose 
adjustments as needed 
 Develop PK washout study simultaneously to older age groups 
 Include LBW & pre-term into study design at the onset 
 Utilize all available modelling methodologies for ensuring proper dose in 
the newborn/ infant age group 
 Ensure adequate enrolment of pregnant women in adult FDC studies 
(similar to 1026s) and gather needed PK data for newborn drug 
development 
 Integrate pregnancy data with washout PK & newborn drug development 
FTC 
Merits: 
 Known safety and dosing in children 
 Ongoing development with TAF 
 
Concerns: 
 Currently none 
 
 
TAF 
Merits: 
 Better bone and renal toxicity compared to TDF 
 Low dose per kg, therefore small pill 
 
Concerns: 
 Hyperlipidaemia, other  toxicity data still being 
collected & interpreted 
 Uncertain dosing with rifampin  
 Comparatively slow paediatric timeline (F/TAF)  
Access to TAF for independent investigations without 
Dolutegravir 
Merits: 
 High barrier to resistance 
 Once daily dosing 
 FDA approved for 6 to 18 year olds  (30 kg and up) 
 Alternative first-line for adults in guidelines and 
therefore incentive for more drug production and 
utilization in children 
 Low dose per kg, therefore small pill 
 Ongoing trials can provided needed data with 
IMPAACT 1093 to provide dosing and ODYSSEY to 
compare DTG to other regimens  
Concerns: 
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